Phase I trial of a measles virus derivative producing CEA (MV-CEA) in patients with recurrent glioblastoma multiforme (GBM)
Latest Information Update: 18 Sep 2021
At a glance
- Drugs MV CEA (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- 02 Jan 2020 Biomarkers information updated
- 28 Nov 2012 New source identified and integrated (Mayo Clinic).
- 13 Sep 2011 Planned end date changed from 1 Jun 2011 to 1 Jun 2013 as reported by ClinicalTrials.gov.